Author:
Savulescu Camelia,Krizova Pavla,Valentiner-Branth Palle,Ladhani Shamez,Rinta-Kokko Hanna,Levy Corinne,Mereckiene Jolita,Knol Mirjam,Winje Brita A.,Ciruela Pilar,de Miguel Sara,Guevara Marcela,MacDonald Laura,Kozakova Jana,Slotved Hans-Christian,Fry Norman K.,Pekka Nuorti J.,Danis Kostas,Corcoran Mary,van der Ende Arie,Vestrheim Didrik F.,Munoz-Almagro Carmen,Sanz Juan-Carlos,Castilla Jesus,Smith Andrew,Colzani Edoardo,Pastore Celentano Lucia,Hanquet Germaine
Funder
Astellas Pharma US
European Centre for Disease Prevention and Control
Pfizer
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference50 articles.
1. World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper –February 2019. WER. 2019;94:85-103.
2. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study;Andrews;Lancet Infect Dis.,2014
3. European Medicines A. Synflorix: EPAR – Product information. Annex I - Summary of product characteristics. 2013.
4. European Medicines A. Prevenar 13: EPAR – Product information. Annex I - Summary of product characteristics. 2014.
5. European Medicines A. Assessment Report for Synflorix. Procedure No. EMEA/H/C/000973. 2009.